Liver and biliary tract cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 92
• PD-L1 51
• TP53 3
• PI3K 0
• mTOR 1
• AKT 0
• STAT3 1
• VEGF 20
• FGFR 22
• GPC3 38
• CTNNB1 5
• YAP 0
• HER2 28
• MAPK 0
• NRF2 0
• HIF-1 0
• PPAR 0
• ERK 0
• AMPK 0
• EGFR 8
• STING 0
• CTLA-4 20
• MYC 0
• IDH 6
• JAK 0
• JNK 0
• PTEN 0
• GPX4 0
• KRAS 8
• BCL-2 0
• HSP90 0
• IL-6 1
• PSMA 8
• MET 1
• GLP-1 1
• BRAF 3
• EZH2 0
• NLRP3 0
• CLDN18 10
• MEK 0
• B7-H3 5
• COX-2 0
• HDAC 0
• CXCR4 0
• HMGB1 0
• METTL3 0
• SIRT1 0
• TLR4 0
• MMP-9 0
• TNF 0
• PARP 2
• PCSK9 0
• TIGIT 2
• TIM-3 1
• CDK4/6 0
• IL-17 0
• RAS 2
• SGLT2 0
• CD47 0
• IL-15 2

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · U19

  Rational hepatitis C virus vaccine design informed by mechanisms of spontaneous clearance or persistence of infection

  Johns Hopkins University· Baltimore, United States· US$2,849,722 awarded in fiscal year 2026· until Jul 2031

• NIH NCI · R44

  Overcoming Immune Evasion in Hepatocellular Carcinoma with Engineered T-Cell Therapy

  March Biosciences Inc· Houston, United States· US$399,003 awarded in fiscal year 2026· until Aug 2027

• NIH NIDDK · R01

  Stakeholder Engagement and Modeling for Adoption of a Novel Cirrhosis Detection Algorithm

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$810,994 awarded in fiscal year 2026· until Jun 2030

• NIH NIAAA · R16

  Phytol and alcohol-associated liver disease

  Marshall University· Huntington, United States· US$146,549 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  Assessment of sound waves from liver vessels via artificial intelligence to detect liver cancer

  University of Minnesota· Minneapolis, United States· US$18,735 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spain· EU contribution €209,915· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding Neural Circuits in Cholangiocarcinoma (LIVER-CIRCUITS)

  Technische Universitaet Dresden· Dresden, Germany· EU contribution €1,500,000· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Malignant Cholangiocyte Subpopulations that Drive Chemoresistance in Cholangiocarcinoma (RESIST-CCA)

  Humanitas Mirasole Spa· Rozzano (Mi), Italy· EU contribution €193,643· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multiscale 3D virtual histology with non-destructive x-rays (XHIST)

  Danmarks Tekniske Universitet· Kongens Lyngby, Denmark· EU contribution €150,000· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Mechano-metabOlic Responsive nanoPlatform for HeterogEnous tUmor Suppression (MORPHEUS)

  Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe· Valencia, Spain· EU contribution €2,499,745· until Aug 2031

  The disease is named only in the funder's project summary, not in the title.

10 of 874 running projects, newest first. Listed amounts together: US$476.2m + €133.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

  NCT06690281· National Cancer Institute (NCI)· Updated 11 Sept 2025

  “PI left NIH.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

  NCT06690281· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 109
• Organoids 40
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 34
• Gene Expression Profiling 281
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 9
• Exome Sequencing 19
• Proteomics 119
• Metabolomics 73
• Mass Spectrometry 23
• Flow Cytometry 66
• Immunohistochemistry 125
• Liquid Biopsy 34
• Circulating Tumor DNA 41
• Xenograft Model Antitumor Assays 443
• Positron-Emission Tomography 35
• Magnetic Resonance Imaging 376
• Machine Learning 198
• Deep Learning 114
• Cohort Studies 184
• Genome-Wide Association Study 42

• Single-cell and spatial transcriptomics define a C3-centred multicellular ecology in colorectal liver metastasis.

  Funct Integr Genomics, Nov 2026

• Endothelial circadian rhythm genes as prognostic modulators of tumor progression and immune interactions: insights from pan-cancer single-cell RNA sequencing.

  Int J Surg, Nov 2026

• Enhancing cell type deconvolution in spatial transcriptomics through incorporating multiple reference panels.

  PLoS Genet, Nov 2026

• Single-cell and spatial transcriptomics in intrahepatic cholangiocarcinoma: spatial immune ecosystems, metabolic remodeling, and immunotherapeutic implications.

  Front Immunol, Oct 2026

• integrating single-cell transcriptomics and chromatin accessibility profiling to decipher the molecular landscape of Hepatocellular carcinoma.

  PLoS One, Oct 2026

• Somatic Mutation-Informed Transcriptional Architecture of Hepatocellular Carcinoma: A Multiomics Study Centered on TP53.

  Hum Mutat, Oct 2026

• Single-cell and spatial multi-omics combined with machine learning to unravel the heterogeneity of cholangiocarcinoma and the WFDC3-mediated prognostic regulatory mechanisms.

  Front Immunol, Oct 2026

• State-Dependent Decoupling of a CREM-Centric cAMP-Responsive Regulon and Survival in Hepatocellular Carcinoma.

  Int J Med Sci, Oct 2026

• Graph attention network-driven single-cell omics analysis reveals how B4GALNT1-mediated glycosylation remodelling of the ferroptosis-pyroptosis network promotes drug resistance in hepatocellular carcinoma.

  Clin Transl Med, Oct 2026

• Decoding the spatial logic of immune evasion in hepatocellular carcinoma: from single-cell profiling to spatial omics.

  Front Immunol, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.